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Prevalence of the Metabolic Syndrome in a Rural
Turkish Population: Comparison and Concordance of
Two Diagnostic Criteria*
Aim: This study was performed to compare the prevalence of the metabolic syndrome (MES) according to the
International Diabetes Federation (IDF) and Adult Treatment Panel III (ATPIII) definitions in a population-based
sample and to determine the concordance of the definitions.
Materials and Methods: A total of 244 adults aged ≥20 years (145 women and 99 men), selected
systematically from household registration cards in a rural village in West Anatolia, were analyzed. Kappa test
was done to examine the agreement between the definitions.
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Results: The mean age of the group was 46.9 ± 14.9 years. The prevalence of MES using ATPIII and IDF
definitions was 38.1% and 41.4%, respectively. MES prevalence increased with age 50 in both genders using
both criteria (P < 0.001). Only 9.8% and 6.3% of the population had none of the components of MES
according to ATPIII and IDF, respectively. The agreement rate between the IDF and ATPIII was 91.1% ±
0.04% (Kappa = 0.812). The subjects defined only with ATPIII and not IDF were all men and had lower body
mass index and waist circumference than those defined by both ATPIII and IDF.
Conclusions: The MES was common among our population using either ATPIII or IDF definition. The
agreement between the two definitions was good. The insufficiency of IDF definition for detecting leaner but
metabolically abnormal men should be kept in mind. Screening, prevention and treatment interventions for
this syndrome seem to be organized promptly.
Key Words: Metabolic syndrome, prevalence, definitions, Turkish

Türkiye’de K›rsal Bir Alanda Metabolik Sendrom Prevelans›: ‹ki Tan› Kriterinin
Karﬂ›laﬂt›r›lmas› ve Uyumu
Amaç: Bu çal›ﬂman›n amac›, topluma dayal› bir örneklemde metabolic sendrom (MES) prevelans›n› Uluslararas›
Diyabet Federasyonu (IDF) ve Eriﬂkin Tedavi Paneli III (ATPIII) tan›mlar› temelinde karﬂ›laﬂt›rmak ve iki tan›m›n
uyumunu araﬂt›rmakt›r.
Yöntem ve Gereç: Çal›ﬂmaya Bat› Anadolu’daki k›rsal bir kasabada ev halk› tespit fiﬂlerinden sistematik olarak
seçilen 20 yaﬂ ve üzerindeki 244 yetiﬂkin al›nd›. Tan›mlar aras›ndaki uyum Kappa test ile araﬂt›r›ld›.
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Bulgular: Grubun yaﬂ ortalamas› 46,9 ± 14,9 y›ld›. MES prevalans› ATPIII ve IDF tan›mlar›na göre s›ras›yla
% 38,1 ve % 41,4 olarak saptand› ve hem erkek hem de bayanlarda 50 yaﬂ üzerinde MES prevalans›nda art›ﬂ
gözlendi (P < 0,001). ATPIII ve IDF tan›mlar›na göre grubun s›ras›yla sadece % 9,8’i ve % 6,3’ü hiçbir kriteri
taﬂ›m›yordu. IDF ve ATPIII tan›mlar› aras›ndaki uyum oran› % 91,1 ± % 0,04 (Kappa = 0,812) olarak
bulundu. Sadece ATPIII ile MES tan›s› alan ancak IDF tan›m›na göre MES olmayanlar›n hepsi erkekti ve vücut
kitle indeksleri ile bel çevreleri her iki tan›m ile de MES saptananlardan daha düﬂüktü.
Sonuç: Metabolik sendrom prevalans› bölgemizde yüksektir ve iki tan›m aras›nda iyi bir uyum bulunmaktad›r.
IDF tan›m›n›n zay›f ancak metabolik unsurlar› bozuk olan erkekleri saptamada yetersiz kalabilece¤i ak›lda
tutulmal›d›r. Bu sendroma yönelik olarak tarama, önleme ve tadavi giriﬂimlerinin acilen organize edilmesi
gerekli görünmektedir.
Anahtar Sözcükler: Metabolik sendrom, prevelans; tan›mlar, Türkiye

ayfer64@yahoo.com
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Introduction
The metabolic syndrome (MES), which is
characterized by insulin resistance, consists of several
cardiovascular risk factors such as glucose intolerance,
central obesity, dyslipidemia and hypertension (1). It is
associated with an increased risk for the development of
type 2 diabetes (2,3), cardiovascular disease (CVD) (4)
and mortality due to coronary heart disease (CHD) (5,6).
A recent study revealed that in two out of every three
cases, CHD originates from MES among Turkish people
(7). Therefore, it is important to identify subjects with
MES earlier. Several definitions of the MES have been
approved to date for research and/or clinical purposes.
This study aimed to estimate and compare the prevalence
of MES in a rural adult Turkish population using the
definitions proposed by the International Diabetes
Federation (IDF) (8) and the National Cholesterol
Education Program Adult Treatment Panel III (ATPIII) (9)
and to determine the concordance of the definitions.
Materials and Methods
Study Population
The study was conducted in Umurlu, a medically
underserved town in West Anatolia. The study population
included 244 subjects selected among 7276 adults aged
20-80 years from household registration cards by cluster
sampling method from all four districts. The sample size
was calculated on prevalence of 20%, d = 0.05 at a
confidence level of 95% (10).
Measurements
The participants were invited to the primary care
center of the Family Medicine Department after an
overnight fast. Demographic and anthropometric data
were obtained with face-to-face interview. Body weight,
height and waist circumference (WC) were measured for
each subject. Weight and height were measured while
participants wore light clothes without shoes. WC was
measured with a soft tape on standing subjects midway
between the lowest rib and the iliac crest. Body mass
index (BMI) was calculated as a ratio of weight (kg) to
height squared (m). Overweight was defined as BMI ≥25
2
2
kg/m and obesity as ≥30 kg/m (11). Systolic blood
pressure (SBP) and diastolic blood pressure (DBP) were
measured twice at 5-min intervals in the sitting position
after a 10-min rest, and the mean was taken in all
subjects.
160
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Blood samples were drawn after 8-12 h fasting for
the measurement of triglycerides, high-density
lipoprotein-cholesterol (HDL-C), and glucose levels, and
Architect C800 autoanalyzer (Abbott, USA) was used for
measurements. All subjects gave written informed
consent, and the Ethics Committee of Adnan Menderes
University Medical School approved the research protocol
for this study.
Definitions of Metabolic Syndrome
The MES was defined according to the ATPIII and IDF
definitions. Subjects having three or more of the
diagnostic criteria were defined as having MES according
to the ATPIII report (9). These criteria are: 1) Obesity:
WC >102 cm in men or >88 cm in women, 2)
Hypertriglyceridemia: triglyceride ≥150 mg/dl, 3) Low
HDL-C, <40 mg/dl in men and <50 mg/dl in women, 4)
Hypertension: known hypertensives or BP ≥130/85
mmHg, and 5) Dysglycemia: known diabetes mellitus
(DM) or fasting plasma glucose ≥110 mg/dl.
According to the IDF definition (8), for a person to be
defined as having MES, he/she must have a central obesity
(defined as WC ≥94 cm for men and ≥80 cm for women),
plus any two of the following four factors: 1) Raised
triglyceride levels ≥150 mg/dl, or specific treatment for
this lipid abnormality, 2) Reduced HDL-C, <40 mg/dl for
men and <50 mg/dl for women, or specific treatment for
these lipid abnormalities, 3) Raised SBP ≥130 or DBP
≥85 mmHg, or treatment of previously diagnosed
hypertension, and 4) Raised fasting plasma glucose (FPG)
≥100 mg/dl, or previously diagnosed type 2 diabetes.
We divided the subjects with MES into three groups:
subjects identified as MES by IDF but not ATPIII, by
ATPIII but not IDF, and by both IDF and ATPIII as Group
1 (n = 15), Group 2 (n = 7) and Group 3 (n = 86),
respectively.
Statistical Analysis
SPSS 13.0 was used for statistical analysis.
Descriptive statistics are presented as means ± standard
deviations (SD). The categorical variables are given as
percentages. Relations among different groups were
2
analyzed with the χ test. Student’s t-test and one-way
ANOVA were used to compare means and test for
significant differences in anthropometric and metabolic
indices between the groups. Kappa statistics was used to
test the degree of agreement between the two
definitions. A p value <0.05 was considered statistically
significant.
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The mean age of the 244 subjects in the study was
46.9 ± 14.9 years. Of those, 145 were women (59.4%)
and 99 were men (40.6%). Of the total, 70.5% were
overweight or obese. The characteristics of the subjects
are summarized in Table 1. Women had higher BMI and
HDL-C and lower triglyceride levels than men. Other
characteristics were not significantly different between
the two groups.
The crude prevalence of MES according to the ATPIII
and IDF criteria was 38.1% and 41.4% for total; 41.4%
and 46.2% in women, and 33.3% and 34.3% in men,
respectively. The prevalence of MES was higher in women
than in men using both definitions; however, this
difference was not statistically significant (P = 0.204 for
ATPIII and p = 0.065 for IDF).
The prevalence of MES using both the ATPIII and IDF
criteria increased significantly with age 50 in both
genders - in women from 30.3% to 58.9% and 34.8%
to 64.3%, respectively; and in men from 17.6% to
50.0% and 19.6% to 50.0%, respectively (P < 0.001
for all). The prevalence of MES increased with ageing and
this finding is shown in Figure.
The prevalence rates of the individual components and
number of items of MES according to the two different
criteria are listed in Table 2. Low HDL-C and abdominal
obesity was the most common abnormality in men
(78.8%) and in women (82.1%), respectively, by the IDF
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Figure. Prevalence of metabolic syndrome with ATP III and IDF definitions according to age groups.

definition. According to ATPIII, low HDL-C was the most
common abnormality for both men (78.8%) and women
(79.3%). Abdominal obesity was markedly higher in
women than men using both definitions (P < 0.001).
Only 9.8% and 6.3% of the population had none of the
components according to ATPIII and IDF, respectively,
and of the total, 52.1% and 61.2% had one or two
components of the syndrome by ATPIII and IDF,
respectively.
The number of subjects identified by only ATPIII, only
IDF or both criteria were 93, 101 and 86, respectively.
The agreement rate, which is the percentage of
participants who were classified as either having or not
having the MES by both definitions, was 91.1% ± 0.04%
(Kappa = 0.812, P < 0.001). Regarding gender, the
agreement rate between the IDF and ATPIII definitions
was 84.8% ± 0.08% in men (Kappa = 0.662, P <

Table 1. Characteristics of the subjects by gender.
Women
(n = 145)

Men
(n = 99)

Total
(n = 244)

Age (years)

46.6 ± 14.6

47.6 ± 15.4

46.9 ± 14.9

WC (cm)

93.9 ± 15.4

92.1 ± 11.9

93.1 ± 14.1

2

BMI (kg/m )

29.4 ± 5.7*

26.5 ± 4.6

28.2 ± 5.5

SBP (mmHg)

124.6 ± 23.2

126.0 ± 24.7

125.2 ± 23.8

DBP (mmHg)

80.3 ± 13.7

82.1 ± 15.6

81.0 ± 14.5

FBG (mg/dl)

95.1 ± 29.8

97.7 ± 26.6

96.2 ± 28.5

Triglyceride (mg/dl)

118.9 ± 66.3

142.2 ± 81.7**

128.4 ± 73.7

HDL-C (mg/dl)

40.9 ± 11.5*

33.4 ± 9.7

37.9 ± 11.4

Results are expressed as means ± SD. WC: Waist circumference. BMI: Body mass index.
SBP: Systolic blood pressure. DBP: Diastolic blood pressure. FBG: Fasting blood glucose.
HDL-C: High-density lipoprotein cholesterol.
*Comparison by gender, P < 0.001; ** Comparison by gender, P < 0.05.
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Table 2. Prevalence of the metabolic syndrome components according to two definitions of the
metabolic syndrome, by gender.
Factor

Women
(n = 145)

Men
(n = 99)

Total
(n = 244)

50.4% (123)

ATP III criteria
Central obesity

66.9% (97)*

26.3% (26)

Hypertriglyceridemia

26.2% (38)

35.4% (35)

29.9% (73)

Low HDL-cholesterol

79.3% (115)

78.8% (78)

79.1% (193)

Hypertension

43.4% (63)

44.4% (44)

43.9% (107)

Hyperglycemia

10.3% (15)

12.1% (12)

11.1% (27)

Metabolic syndrome

41.4% (60)

33.3% (33)

38.1% (93)

None

8.3% (12)

12.1% (12)

9.8% (24)

One

21.4% (31)

26.3% (26)

23.4% (57)

Two

29.0% (42)

28.3% (28)

28.7% (70)

Three or more

41.4% (60)

33.3% (33)

38.1% (93)

82.1% (119)*

41.4% (41)

65.6% (160)

Hypertriglyceridemia

26.2% (38)

35.4% (35)

29.9% (73)

Low HDL-cholesterol

79.3% (115)

78.8% (78)

79.1% (193)

Hypertension

43.4% (63)

44.4% (44)

43.9% (107)

Hyperglycemia

22.1% (32)

25.3% (25)

23.4% (57)

Metabolic syndrome

46.2% (67)

34.3% (34)

41.4% (101)

None

7.6% (9)

2.4% (1)

6.3% (10)

One

36.1% (43)

14.6% (6)

30.6% (49)

Two

27.7% (33)

39.0% (16)

30.6% (49)

Three or more

28.5% (34)

43.9% (18)

32.5% (52)

ATP III items

IDF criteria
Central obesity

IDF items **

*Comparison by gender P < 0.001; ** Out of central obesity.

0.001) and 95.2% ± 0.03% in women (Kappa = 0.902,
P < 0.001), as shown in Table 3.
Clinical parameters of the three groups are compared
in Table 4. The seven subjects in Group 2 were all men
(as seen in Table 3) and they fulfilled at least three of the
other criteria. These men in Group 2 had lower BMI and
WC than subjects in Group 3.

Discussion
This was the first study in our population to compare
the prevalence of MES according to ATPIII and IDF and
determine the concordance of these definitions. Of the
162

total, more than one-third had MES and these two
definitions showed good agreement for diagnosis, except
that some leaner men with metabolic abnormalities were
undetected using IDF.
In this study, although the prevalence of MES was
higher in women than in men using both definitions, a
significant difference was not observed. This finding is
consistent with the results of a study from Vietnam (12)
but not concordant with the literature, which generally
reveals significantly higher MES rates in women (13-16).
This might be related to central obesity, lower HDL-C and
higher triglyceride levels in men in our group than the
others (17).
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Table 3. Agreement between ATP III and IDF definitions in diagnosing metabolic syndrome.
All (n = 244)

ATP III definition

Kappa

Metabolic syndrome
IDF definition

Metabolic syndrome

Present

Absent

Total

Present
Absent
Total

86
7
93

15
136
151

101
143
244

Women (n = 145)

ATP III definition

0.812

Kappa

Metabolic syndrome
IDF definition

Metabolic syndrome

Present

Absent

Total

Present
Absent
Total

60
0
60

7
78
85

67
78
145

Men (n = 99)

ATP III definition

0.902

Kappa

Metabolic syndrome
IDF definition

Metabolic syndrome

Present

Absent

Total

Present
Absent
Total

26
7
33

8
58
66

34
65
99

In our study, the prevalence rate of the MES
according to the IDF criteria was higher than the rate
using the ATPIII, and this could be attributed to the more
stringent cut-off points for waist circumference, which is
the first most common abnormality in our population.
Some other studies also reported higher MES prevalence
rates with IDF than ATPIII (14,15).

0.662

As our results reveal that less than 10% of the
population had none of the components and more than
half are at great risk for developing MES, with the
presence of at least one or two criteria, it is important to
increase awareness and take preventive steps on this issue.

We found the prevalence of MES diagnosed using
both definitions increased significantly with age 50 in
both genders. Many other studies have also reported that
MES prevalence increases with age (12,13,16,18-22).

These two definitions had a good agreement in
identifying subjects with MES in our population. Our
results present higher agreement rates than the other
studies (15,26). The agreement between the definitions
was poorer in men than in women and this might be
related to the fact that lean men went undetected by IDF.

According to the IDF, the most common abnormalities
were abdominal obesity and low HDL-C in women and
men, respectively, and this finding is parallel with results
of other studies (23,24). Low HDL-C was the most
common abnormality in both genders by ATPIII and this
was also shown in other Turkish studies (24,25), which
may be explained by the low mean level of HDL-C in
Turks (17).

This study showed that subjects with MES defined
only by ATPIII and not IDF had lower BMI and WC
compared to subjects defined with both ATPIII and IDF.
This could be interpreted as indicating that the IDF
definition may not be sufficient to identify some leaner
subjects, especially men, with other metabolic
abnormalities. Some recent studies also pointed out this
finding (15,26-29).
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Table 4. Clinical parameters of the subjects having IDF- and/or ATPIII-defined metabolic
syndrome.
Group 1 (n = 15)
IDF+/ATPIII-

Group 2 (n = 7)
IDF-/ATPIII+

Group 3 (n = 86)
IDF+/ATPIII+

Age (years)

57.1 ± 11.9

60.7 ± 6.9

52.8 ± 12.3

WC (cm)

98.5 ± 11.4

87.4 ± 4.0*

104.1 ± 10.4

BMI (kg/m2)

29.7 ± 3.9

24.8 ± 3.8*

32.0 ± 4.6

SBP (mmHg)

132.5 ± 17.8

145.0 ± 23.1

139.3 ± 24.7

DBP (mmHg)

83.2 ± 12.5

90.7 ± 13.4

88.6 ± 17.5

FBG (mg/dl)

97.2 ± 12.5

127.0 ± 60.7

106.9 ± 37.1

Triglyceride (mg/dl)

127.5 ± 75.4

221.0 ± 105.8

169.5 ± 84.1

35.7 ± 9.1

30.9 ± 5.7

33.5 ± 8.8

HDL-C (mg/dl)

* Comparison of Group 2 and Group 3, P < 0.001.

In summary, MES is common among our population
according to both definitions, and the agreement between
ATPIII and IDF definitions was very good, especially in
women. IDF definition may miss some non-obese men
with other metabolic abnormalities. Knowledge of the
high prevalence of MES in our population makes it critical
to plan prevention and health care interventions.
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